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Background: Following infection with Mycobacterium tuberculosis (M.tb), children are 
more susceptible to develop disease particularly extrapulmonary disease than adults. 
The exact mechanisms required for containment of M.tb are not known, but would be 
important to identify correlates of protection.
Objective: To comprehensively analyze key immune responses to mycobacteria 
between HIV-negative children with extrapulmonary TB (EPTB) compared to children 
with pulmonary TB (PTB) or healthy controls.
Methods: Whole blood was stimulated in vitro with mycobacteria for 24 h or 6 days 
to induce effector and memory responses. CD4, CD8, γδ, regulatory T cells, and their 
related cytokines were measured. Samples of children with tuberculosis (TB) disease 
were analyzed both at time of diagnosis and at the end of TB treatment to determine if 
any differences were due to TB disease or an underlying host phenotype.
results: Seventy-six children with TB disease (48 with PTB and 28 with EPTB) and 83 
healthy controls were recruited to the study. The frequency of CD4+CD25+CD39+FOXP3+ 
regulatory T cells and secreted IL10 were significantly higher in children with TB compared 
to healthy controls. IFNγ-, IL17-, and IL22-producing γδ T cells, IL22-producing CD4+ 
T cells and secreted pro-inflammatory cytokines (IFNγ, IL1β, and TNFα) were significantly 
lower in children with TB disease compared to healthy controls. IFNγ-producing CD4+ 
T cells and Ki67+-proliferating CD4+ T cells, however, were present in equal numbers 
in both groups. Following treatment, these immune parameters recovered to “healthy” 
levels or greater in children with PTB, but not those with extrapulmonary TB.
conclusion: In children with TB disease, a predominantly immune regulatory state is 
present. These immune findings do not distinguish between children with PTB and EPTB 
at the time of diagnosis. Following treatment, these inflammatory responses recover in 
PTB, suggesting that the effect is disease specific rather than due to an underlying host 
defect.
Keywords: tuberculosis, extrapulmonary, pediatric, mycobacterial immunity, regulatory T cells
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inTrODUcTiOn
Of the estimated 10.4 million new cases of tuberculosis (TB) 
annually, at least 1million (10%) occurred in children (1). The 
BCG vaccine confers partial protection against disseminated TB 
in young children but has variable efficacy against pulmonary 
TB (PTB), and better vaccines are urgently required. Following 
infection, children have a higher risk not only of progression 
to disease but also of dissemination or extrapulmonary TB 
(EPTB) and death, and this risk decreases with increasing age 
(2, 3). Characterizing the mycobacterial-specific immune respon-
ses in children affected by either PTB or EPTB may provide 
insight into the mechanisms of immune containment, which are 
essential in the search for correlates of protection, so urgently 
required for a better vaccine against TB.
T cell immunity is well recognized as essential for protection 
against TB infection and disease, and CD4+ T  cell depletion, 
such as seen in HIV, is a contributing factor to TB susceptibil-
ity. Mycobacterial-specific CD4+ T cells primarily produce Th1 
cytokines, which include IFNγ, IL-2, and TNFα. However, recent 
studies report a lack of correlation between immune protection 
imparted by BCG and IFNγ, produced by CD4+ T  cells (4, 5). 
Hence, these data support the notion that although CD4+ 
T cells and IFNγ are important components of an effective anti- 
mycobacterial immune response, they do not fully explain 
observed differences in host susceptibility to TB. Other cell 
types, such as γδ, Th17, and regulatory T cells are also considered 
important, but these T cell populations have not been studied in 
children with PTB or EPTB (6, 7).
Animal models have established that the presence of an exces-
sive number of γδ T cells producing IL17 lead to severe dissemi-
nated disease (8, 9). It is likely in humans that the balance between 
mycobacterial antigen-specific IL17 and IFNγ-producing T cells 
is also of importance in protection against TB disease and in par-
ticular, EPTB. This has not been examined in children but would 
be compatible with their known higher susceptibility to progress 
to pulmonary and disseminated disease, given the relatively 
impaired production of IFNγ in young age (10).
Increased numbers of regulatory T cells have been found in 
adults with TB infection and disease in comparison to healthy 
controls, particularly in patients with EPTB, a finding that 
persists even in patients with “cured” EPTB (11–13). Regulatory 
T cells expressing FOXP3 correlate well with regulatory activity; 
however, the FOXP3 marker is also present in activated T cells in 
the presence of IL2. Recently, CD39 was found to be expressed on 
a subpopulation of regulatory T cells. CD39 is an ectonucleoti-
dase that cleaves ATP in a rate-limiting step to form AMP, which 
can then be cleaved by CD73 to form adenosine. Extracellular 
ATP has multiple pro-inflammatory effects, and its removal may, 
therefore, have a net anti-inflammatory influence. CD4+CD25+
CD39+FoxP3+ cells are found to suppress IL17 production and 
are increased in TB patients after antigen-specific stimulation. 
Depletion of these cells resulted in increased antigen-specific 
IFNγ CD4 T cell responses (14). We chose to measure CD4+CD2
5+CD39+FOXP3+ T cells based on the most recent literature, sug-
gesting that these markers most accurately identify functionally 
suppressive regulatory T cells in humans, influence mycobacterial 
specific responses in patients with TB disease and play a role in 
influencing the immune response to novel TB vaccines (15, 16). 
To date, there are no studies that have examined the role of regula-
tory T cells in different clinical manifestations of pediatric TB.
Based on these interesting data, we hypothesized that the 
mycobacterial-specific immune response in children with TB, 
in particular EPTB, would have an increased frequency of both 
IL17-producing γδ T cells and regulatory T cells in comparison 
with healthy controls. We aimed to characterize these T  cell 
populations in a group of HIV-negative children with PTB and 
EPTB compared to healthy children without any evidence of 
sensitization to Mycobacterium tuberculosis (M.tb). The aim of 
this study was to compare immune responses to mycobacteria in 
children with PTB, EPTB, and healthy controls.
Our data show that regulatory T  cells are increased in 
children with TB disease compared to healthy controls, but do 
not discriminate between pulmonary and extrapulmonary TB 
disease. This is associated with suppression of pro-inflammatory 
cytokines, which corresponds with recent gene expression stud-
ies (17–20). Furthermore, as these immune responses were also 
examined following treatment, we can now confirm they are 
TB-disease specific, rather than a product of young age or host 
differences.
MaTerials anD MeThODs
Participant enrollment and classification
The study was conducted at Red Cross Children’s Hospital 
(RCH) in Cape Town, South Africa. Children between birth and 
16 years were enrolled to three different groups: pulmonary TB 
(PTB) disease, extrapulmonary TB (EPTB) disease, and healthy, 
non-M.tb sensitized children. Children with TB disease pre-
sented to RCH with symptoms consistent with active TB and the 
following clinical details were evaluated: presenting symptoms, 
history of TB contact, CXR/radiological findings, microscopy, 
and culture for M.tb, and clinical examination findings. Children 
with culture-confirmed or GeneXpert-positive disease were clas-
sified as “confirmed” TB. Children who fitted the clinical criteria, 
but did not have microbiological confirmation, were treated 
for TB disease, and responded to treatment were classified as 
“unconfirmed” TB. TB disease extending beyond the pleural 
cavity was classified as EPTB. Children were excluded if they had 
received treatment for TB lasting longer than 72 h, they did not 
live in Cape Town, they were unable to attend follow-up visits, 
or informed consent was not given.
Healthy controls were recruited from well children who pre-
sented to RCH for elective surgical interventions. An in-house 
interferon gamma release assay (IGRA) was used to determine 
M.tb sensitization status; children with a positive IGRA were 
further evaluated for active TB but not included in this analysis. 
Children with a negative IGRA were classified as healthy controls. 
Exclusion criteria for healthy controls were known contact with 
TB; prior treatment for TB, history of recurrent infections, or 
hospital admissions; persistent cough for longer than 4  weeks; 
intercurrent febrile illness; and failure to thrive or known immu-
nodeficiency. All children had received BCG vaccination at birth, 
and only HIV-negative children were included in the study.
TaBle 1 | Demographic and clinical characteristics of study population.
Tuberculosis (TB) disease healthy 
controls 
n = 83Pulmonary 
n = 48
extrapulmonary 
n = 28
Median age in years (range) 3.75 (0.2–13) 5.2 (0.5–11.75) 2 (0.3–11.1)
Female gender (%) 20 (42) 13 (45) 30 (36)
TST in mm (range) 14 (0–34) 14 (0–30) NA
Culture or GeneXpert 
confirmation (%)
23 (48) 19 (68) NA
CNS disease (%) NA 8 (29) NA
Abdominal disease (%) NA 7 (25) NA
Pleural effusion (%) NA 7 (25) NA
Other (pericarditis, bone/
joint, skin, genitourinary) (%)
NA 7 (25) NA
MDR TB (%) 4 (8) 3 (11) NA
Some children had more than one clinical manifestation of extrapulmonary TB, hence 
% add up to greater than 100%.
TST, tuberculin skin test; CNS, central nervous system; MDR, multidrug-resistant 
tuberculosis.
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Blood collection, stimulation, and 
cryopreservation
Blood samples from children with TB disease were taken within 
48 h of enrollment and repeated after completion of 6 months 
treatment.
Heparinized blood was incubated within 4 h with BCG (SSI 
strain, 5  ×  105cfu/ml), as previously described (21). Medium 
served as negative control; staphylococcal enterotoxin B (SEB, 
10 µg/ml final concentration; Sigma, UK) was used as positive 
control. Brefeldin-A was added for the last 5 h of the 20-h incuba-
tion. Cells were then harvested, fixed, and cryopreserved.
It was not possible to evaluate FOXP3 expression directly 
ex vivo. FOXP3+ regulatory T cells were identified in unstimu-
lated whole blood which was incubated for 20 h, including with 
Brefeldin for the final 5 h.
A further aliquot of whole blood (diluted 1:10 in RPMI 1640) 
was incubated with BCG (SSI, 2.5 × 106 cfu/ml) for 6 days for 
a Ki67 lymphoproliferation assay as previously described (22). 
Medium and SEB (5 µg/ml final concentration) served as nega-
tive and positive controls, respectively. To assess intracellular 
cytokine production, 10 ng/ml phorbol 12-myristate 13-acetate 
(PMA, Sigma-Aldrich), 1.5  µg/ml ionomycin (Sigma-Aldrich), 
and 1.5  µg/ml Brefeldin A were added during the last 5  h of 
culture. Cells were then harvested, stained with a viability dye, 
fixed, and cryopreserved.
Prior to the addition of PMA/Ionomycin/Brefeldin, 500 µl of 
supernatant was removed and stored at −80°C for subsequent 
analysis by multiplex ELISA (Bio-plex Pro™ Human Th17 
Cytokine Panel) to determine levels of secreted cytokines.
cell staining and Flow cytometric 
analysis
Cryopreserved cells were thawed, washed, and permeabilized 
with Perm/Wash solution (BD Biosciences). Cells were then 
incubated at 4°C for 1 h with fluorescence-conjugated antibod-
ies directed against surface antigens and intracellular cytokines. 
For detection of the transcription factor FOXP3, a nuclear 
permeabilization buffer (eBioscience, San Diego, CA, USA) was 
used in place of the Perm/Wash solution as per manufacturer’s 
protocol. The following fluorescence-conjugated antibodies 
were used: anti-CD3 PacBlue, anti-γδ TCR PE, anti-CD27 
PECy7, anti-CD25 APC, anti-IFNγ Alexafluor 700, anti-IL17A 
Alexafluor 647, anti-Ki67FITC (BD biosciences, San Jose, CA, 
USA); anti-CD45RA QDot655, anti-CD8 QDot605, anti-CD4 
QDot605 (Invitrogen, Eugene, OR, USA); and anti-CD39 FITC, 
anti-IL22 PerCP-Efluor710, and anti-FOXP3 PE (eBioscience, 
SanDiego, CA, USA).
The entire sample was acquired on a BD LSRFortessa Flow 
Cytometer using FACSDiva software (BD Biosciences, San Jose, 
CA, USA). Compensation was performed using compensation 
beads.
secreted cytokine Measurement
Supernatants from whole blood stimulated for 6 days with BCG 
were thawed. Concentrations of IL-1β, IL-4, IL-6, IL-10, IL-17, 
IL-22, IL-23, IFNγ, and TNFα were measured for all samples 
by Milliplex MAP Multiplex Immunoassay (based on Luminex 
MAP technology; Millipore) on a Bio-Rad Luminex 100 Bio-Plex 
Liquid Array Multiplexing System Fluorescent Reader, according 
to the manufacturer’s instruction. The following concentrations 
of the standards in 200 ml assay buffer were used: 10,000, 2,000, 
400, 80, 16, and 3.2 pg/ml.
Data analysis
All flow cytometry data was analyzed using FlowJo v9.4.11 
(TreeStar, Ashland, OR, USA). Combinations of antigen-specific 
cytokine-producing cells were determined by Boolean Gating in 
FlowJo.
SPSS (version 21) and GraphPad Prism (version 5.0a, 2008) 
were used for statistical analysis of multiparameter flow cyto-
metry data. Negative control values for cytokine expression 
were subtracted from BCG-induced responses. An empiric 
cutoff value of 0.01% was defined as positive (23). Differences 
between groups were calculated using either Mann–Whitney 
or Kruskal–Wallis analysis of variance. For correlations, a 
Spearman coefficient for non-parametric data was calculated. 
All tests were two-tailed, and a value of p < 0.05 was considered 
significant.
resUlTs
clinical characteristics of Patients with 
TB Disease and healthy children
One hundred fifty-nine children were recruited; 76 had TB 
disease with a broad clinical spectrum of which 42 (55%) were 
confirmed, 83 were healthy controls. The demographic and clini-
cal characteristics are shown in Table 1. There was no significant 
difference in median age between children with PTB and those 
with EPTB; however, the healthy children were younger.
We first investigated CD4 T  cell responses in children 
with confirmed and unconfirmed TB and did not find any 
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significant differences. These two groups were subsequently 
combined to analyze differences between the TB cohort and 
healthy controls before proceeding to analyses according to 
disease phenotypes.
antigen-specific cD4+, γδ+, and cD8+  
T cell cytokine Production and 
Proliferation
Following in  vitro stimulation with BCG, production of IFNγ 
by CD4+ T cells was not significantly different between children 
with TB disease compared to healthy children [0.1% (IQR 
0.0–0.24)% vs 0.11% (IQR 0.02–0.28); p =  0.5]. BCG-specific 
production of IL17 by CD4+ T  cell was decreased in children 
with TB disease compared to healthy. However, the number of 
non-responders in both groups was very high and the percent-
age of cytokine producing cells very low, hence this should be 
interpreted with caution. BCG-specific CD4+ T cell production 
of IL22 was significantly suppressed in children with TB disease 
compared to healthy children [0% (IQR 0–0.04) vs 0.03% (IQR 
0–0.08); p = 0.0017] (Figure 1B).
IFNγ production by γδ T  cells was significantly lower in 
children with TB disease compared to healthy children [0% (IQR 
0–0) vs 0.24% (IQR 0–1.18); p < 0.0001], possibly due to a high 
number of non-responders in the TB cohort. The pattern was the 
same for IL17 but not for IL22 (Figure 1D).
We also analyzed the CD4+ and γδ+ T cell responses induced 
by the positive control, SEB (Figures 1C,E), in order to exclude 
generalized non-responsiveness of T cell populations and found 
no significant differences between TB disease and healthy chil-
dren for either cell type or cytokines with good responses to this 
non-specific antigen throughout.
Antigen-specific production of IFNγ, IL17, and IL22 by CD8+ 
T cells was lower in children with TB disease compared to healthy 
children, but there were very high numbers of non-responders in 
all groups (data not shown).
In order to determine potential differences in BCG-specific 
proliferative capacity and cytokine production between the 
groups, a 6-day proliferation assay employing Ki67 was also used. 
Heterogeneity of responses was considerable, but there were no 
significant differences between children with TB disease and 
healthy controls (data not shown).
regulatory T cells Distinguish children 
with TB Disease from healthy children
The frequency of CD4+CD25+CD39+FOXP3+ T  cells were sig-
nificantly increased in children with TB disease compared to 
healthy controls [1.1% (IQR 0.46–1.56) vs 0.43% (IQR 0.18–1.01); 
p < 0.0001] (Figure 2B). Secreted IL10 was measured in super-
natants to explore a possible functional correlate of this T  cell 
population and was found to be significantly higher in children 
with TB disease compared to healthy controls [586 pg/ml (IQR 
265–982) vs 343  pg/ml (IQR 118–625); p <  0.01] (Figure  2C). 
A range of BCG-induced pro-inflammatory cytokines were also 
measured with a number of pro-inflammatory cytokines sig-
nificantly lower in children with TB disease compared to healthy 
controls (Figures 2D–F; Table 2).
T cell assays Do not Distinguish  
between children with Pulmonary  
and extrapulmonary TB Disease at the 
Time of Diagnosis
As we have identified suppression of a number of pro- 
inflammatory and effector responses as described above in 
children with TB compared to healthy controls, we sought to 
establish whether these could distinguish between TB disease 
manifestations. We compared all immune parameters between 
children with PTB (n = 48) to EPTB (n = 28). This analysis did not 
reveal any significant differences in any of the T cell populations 
or their related cytokines between the groups (Figures 3A–E, not 
all data shown).
impact of TB Treatment on T cell 
responses
Our results show that children with disease have suppressed 
pro-inflammatory cytokine production and increased regula-
tory T  cell frequency at the time of diagnosis. We wished to 
establish whether these were induced by TB disease or due to 
an underlying and persistent immune-phenotype, which might 
have pre-disposed this population to contract TB. We therefore, 
repeated all investigations in the children with TB disease fol-
lowing 6 months of TB treatment. Results post-TB therapy were 
compared to the results obtained at the time of diagnosis and to 
healthy controls at the time of enrollment. Follow-up time points 
were not included in healthy children as there was no interven-
tion or prolonged follow-up required, clinically.
Overall, almost all measured immune responses were sig-
nificantly higher post treatment, and a number of significant 
differences between PTB and EPTB emerged. The frequency of 
BCG-specific CD4+ T cells producing IFNγ in both short term 
and proliferation assays was increased in children with PTB com-
pared to the time of diagnosis and compared to healthy children 
(Figures 4A,D), but not in children with EPTB.
The frequency of regulatory T cells had also increased signifi-
cantly in children with PTB by 6 months compared to the time of 
diagnosis, but not in those with ETPB (Figure 4F).
The frequency of BCG-specific γδ+ and CD8+ T cells produc-
ing IFNγ was increased in both assays in children with PTB and 
EPTB, but not in comparison to healthy children (Figures 4B,C).
There were no significant differences in production of IL17 
in CD4+ or γδ+ T  cells following treatment (data not shown). 
However, the production of IL22 by CD4+ T  cells increased 
significantly following treatment in children with both pulmo-
nary and extrapulmonary TB compared to baseline and healthy 
controls (Figure 4E).
DiscUssiOn
Previous studies examining the immune response to M.tb in 
children have been limited in sample size and have primar-
ily focused either on a single T  cell phenotype or on secreted 
cytokines. Our study compared different clinical manifestations of 
TB disease and included a comprehensive range of T cell popula-
tions, using two different immunological assays to capture both 
FigUre 1 | antigen-specific cytokine production in children with tuberculosis (TB) disease compared to healthy children. (a) Gating strategy. 
Representative dot plots from a child healthy control are shown. From left to right, cell doublets were excluded with forward scatter area vs forward scatter height 
parameters. Next, dead cells as stained by a viability stain are gated out and live CD3 T cells gated in. Plotting FSC-A vs SSC-A allows confirmation of the 
lymphocyte population based on size and granularity. Plotting γδ T cell receptor vs FSC-A followed by CD4 vs FSC-A allows the immunophenotyping of these two 
different cell types. Representative dot plots of cytokine expression (IFNγ, IL17, and IL22 in CD4+ T cells) from unstimulated and BCG-stimulated conditions in a 
child with TB are shown. Gates were set using an unstimulated control. Frequencies of IFNγ, IL17, and IL22 producing CD4+ (B,c) and γδ+ (D,e) T cells following 
stimulation of whole blood with BCG (B,D) or SEB (c,e) for 20 h are shown. Responses in TB diseased (n = 76) and healthy children (n = 83) were compared. 
Horizontal bars represent median values. The dotted line represents a cutoff of 0.01 for a positive response. p-Values calculated by Mann–Whitney are displayed.
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effector and central memory T  cell responses. Additionally, we 
tested these responses at time of diagnosis and following treatment.
We found an increased frequency of regulatory T cells in chil-
dren with TB disease, not previously reported, although we did not 
see differences between children with PTB and EPTB. Our results, 
therefore, differ from adult data that reported a 2.3-fold increase in 
FOXP3 expression in patients with EPTB compared to PTB (12). 
The use of the surface marker CD39 may explain the difference 
FigUre 2 | regulatory T cells and the related cytokine il10 are significantly increased in children with tuberculosis (TB) disease compared to 
healthy controls. (a) Gating strategy. From left to right, CD3 vs Times is shown to detect differences in flow. Cell doublets were excluded with forward scatter area 
vs forward scatter height parameters. Plotting FSC-A vs SSC-A allows identification of the lymphocyte population based on size and granularity. CD4+CD3+ T cells 
are identified, followed by CD4+CD25+ T cells. Using FMO gates, FOXP3 and CD39 gates are placed to identify the CD3+CD4+CD25+CD39+FOXP3+ population. 
Frequency of CD4+CD25+CD39+FOXP3+ regulatory T cells in unstimulated whole blood (B) and the secreted level of a key cytokines following 6 days of stimulation 
with BCG (c–F) are shown. The assays were performed for both groups: TB disease (n = 76) and healthy children (n = 83). Horizontal bars represent median 
values. p-Values calculated by a Mann–Whitney test are displayed.
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between our findings and the limited studies in adults. It is also 
possible that regulatory T cells in young children behave differently 
from those in adult patients, where active TB is more likely to arise 
from reactivation or reinfection than the primary infection most 
commonly seen in young children. Infants have been shown to 
have greater numbers of CD45RA+ phenotypically naïve regulatory 
T cells which are functionally different, proliferating, and persisting 
for longer than the CD45RA-regulatory T cells which predominate 
TaBle 2 | secreted cytokine production following Bcg stimulation in 
healthy children vs those with TB disease.
cytokine healthy median (iQr) 
pg/ml
active TB disease 
median (iQr) pg/ml
p-Value
IL1β 4,111 (1,056–4,118) 1,479 (206–4,107) 0.001
IL17F 1,283 (211–4,779) 240 (26–1,543) <0.0001
IFNγ 1,357 (180–2,379) 186 (19–817) <0.0001
TNFα 815 (270–21,848) 380 (73–671) <0.0001
IL10 321 (101–615) 586 (265–982) 0.01
IL6 26,914 (7,390–27,065) 24,140 (9,673–28,354) 0.1
IL22 141 (60–337) 158 (51–339) 0.1
IL23 74 (17–475) 54 (0–242) 0.09
IL4 6.4 (2–19.3) 5.9 (1–42.6) 0.6
Median secreted cytokine levels (picograms per milliliter) with interquartile range for 
each group is shown. A Mann–Whitney test for all comparisons was performed,  
p-values are shown.
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in adults. The role of these different phenotypes of regulatory T cells 
may have been interesting to explore in this cohort (24).
Previous studies have demonstrated suppression of effector 
immune responses, such as IFNγ production by CD4 T  cells 
in children with TB in comparison to healthy controls (25). 
Our data show lack of suppression of Th1 immune responses 
as measured by either the IFNγ production by CD4+ T  cells 
or the Ki67 proliferative capacity of these T cells. However, we 
found suppression of Th17 responses (IL17 and IL22 production 
by CD4 and γδ T  cells) as well as significantly lower levels of 
secreted pro-inflammatory cytokines including IL1β, TNFα, and 
IFNγ, following stimulation of whole blood with BCG for 6 days. 
This finding is in line with adult data, which also demonstrated 
suppressed levels of antigen-specific immune responses to 
mycobacteria at the time of diagnosis (26, 27) and more recently 
a small pediatric study reporting suppressed IFNγ effector 
responses, which were measured as secreted cytokines following 
PPD stimulation after 24 h (28). A number of hypotheses have 
been formulated regarding this phenomenon of antigen-specific 
suppression of immune responses, including compartmentaliza-
tion of relevant cell populations at the site of disease or an active 
and selective depletion of mycobacteria-specific T  cells during 
TB disease (11, 26, 29). It is also possible that M.tb itself induces 
relative immunosuppression as a mechanism for survival in the 
host, in line with transcriptomic data which show downregula-
tion of immune response genes in the presence of M.tb in both 
adults and children (17–20). Whether these findings represent 
“the chicken or the egg” remains to be fully established, but the 
fact that T cell responses recover following treatment in the PTB 
cohort might indicate that it is induced by the disease rather than 
representing a persistent underlying host immuno-phenotype.
In addition to regulatory T  cells and CD4 T  cell responses, 
our study also characterized the role of γδ T cells in the immune 
response to mycobacteria in children with TB. We report that 
although γδ T  cells expand, proliferate, and produce both Th1 
and Th17 cytokines in response to BCG stimulation in children 
with different manifestations of TB disease, they do not appear to 
behave in a counter-regulatory fashion to CD4 T cells, as we had 
originally hypothesized. Dieli et al. showed increased proliferative 
capacity of γδ T cells, but decreased IFNγ production in children 
with TB compared to healthy controls and an increase in IFNγ 
production after treatment (30). Similarly, our data demonstrate 
that BCG-induced γδ T cells produce significantly less IFNγ and 
IL17 in children with active TB disease at the time of diagnosis 
compared to healthy controls, but increase following treatment. 
Interestingly, we did not demonstrate a correlating suppression 
of IL22 production in active TB at the time of diagnosis compared 
to healthy children. In non-human primates with severe TB dis-
ease, unbalanced upregulation of immune gene networks, includ-
ing overexpression of IL22, was demonstrated by Yao et al. (31). 
Scriba et al. described a distinct subset of IL22-producing T cells in 
the lungs of adult patients with TB disease, and IL22 was found to 
be more abundant in both blood and at the disease site of patients 
with pericardial TB disease (29, 32). γδ T  cells have previously 
been identified as the source of IL22 in adults with TB disease 
(33). IL22 is known to either enhance a pro-inflammatory state 
in the presence of IFNγ, TNFα, IL2, and IL17 or in their absence 
is recognized to have immune regulatory and regenerative func-
tions. In our cohort, this latter immune regulatory state appears 
to predominate, with increased regulatory T cells and decreased 
IFNγ and TNFα present in children with active TB disease.
Despite measuring immediate and proliferative responses, the 
assays performed in this study were unable to distinguish between 
pulmonary and extrapulmonary TB. A number of studies have 
explored this previously with discordant results. Verbon et  al. 
demonstrated that unstimulated cytokine levels in serum were 
present in equivalent levels in pulmonary and extrapulmonary 
TB, while Sharma et al. recorded higher levels in miliary TB, a 
form of severe extrapulmonary TB, compared to pleural TB 
(34, 35). Conversely, a number of studies have demonstrated that 
both unstimulated and stimulated levels of pro-inflammatory 
cytokines are present in lower levels in adults with extrapulmonary 
or severe TB disease compared to pulmonary TB (36, 37), both at 
the time of treatment and afterward (38), leading to suggestions 
of an underlying immune defect in those patients who develop 
extrapulmonary TB disease. In particular, regulatory T cells and 
circulating levels of IL10 have been suggested to be increased in 
patients with extrapulmonary TB both during the disease period 
and subsequently (13, 36, 39). These studies were performed in 
adults who are likely to present with reactivation disease and high 
bacterial loads, unlike children who usually develop primary 
progressive paucibacillary disease. It is, therefore, not surprising 
that these results differ from our own findings and between study 
populations.
We repeated all assays in our TB cohorts following completion 
of 6 months treatment to determine whether the study findings 
were possibly due to an underlying susceptibility for TB disease 
or represented a phenomenon induced by active disease. In 
agreement with other investigators, our data show recovery of 
the antigen-specific responses post treatment to levels that were 
of greater magnitude than those reported in healthy children. This 
would indicate that their suppression in face of acute disease rep-
resents a pathogen-induced response. Interestingly, the recovery 
response was of lesser magnitude in children with EPTB. Whether 
this may be attributable to higher bacillary burden at the onset of 
disease or slower clearance rates of mycobacteria cannot be deter-
mined, as we did not have the capacity to collect this information 
as part of our study. It is, however, recognized that patients with 
FigUre 3 | T cell assays did not distinguish between children with pulmonary TB (PTB) disease and children with extrapulmonary TB (ePTB) 
disease. Frequencies of IFNγ-, IL17-, and IL22-producing CD4+ T cells as detected by an intracellular cytokine assay following stimulation of whole blood with BCG 
for 16 h (a), the frequency of CD4+CD25+CD39+FOXP3+ regulatory T cells in unstimulated whole blood (B), and the secreted level of key cytokines following 6 days 
of stimulation with BCG (c,D,e) are shown. The assays were performed in both groups: PTB (n = 48) and EPTB (n = 28). Horizontal bars represent median values. 
The dotted line represents a cutoff of 0.01 for a positive response. p-Values calculated by Mann–Whitney are displayed.
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ETPB have higher rates of culture confirmation and relapse than 
those with PTB, justifying the usually longer treatment course. 
Another explanation may be that these children represent a cohort 
in whom the original BCG vaccine was less effective, but given 
that there were no significant differences in acquired immune 
responses as measured by BCG-specific, IFNγ-producing CD4 
T cells at the time of diagnosis, this seems unlikely. Published data 
have already shown that IFNγ responses measured at 10 weeks post 
BCG vaccination in a Cape Town Cohort could not distinguish 
between infants at risk of TB disease over time, further refuting 
this possibility (5).
Our data show that the frequency of regulatory T  cells is 
increased in both PTB and EPTB following treatment. While this 
could be explained at the time of diagnosis as a response to the 
presence of high levels of antigen, it is an unlikely explanation 
after 6 months of effective treatment for TB. This may represent 
an underlying susceptibility to TB disease in these children. 
Alternatively, the memory recall response to BCG, which results 
in expansion of effector T  cells at the end of treatment, may 
equally induce the expansion of regulatory T cells.
A unique strength of our study is the number of children 
recruited and their thorough clinical and immunological charac-
terization within distinct groups, including healthy controls. It is 
noteworthy that there were no significant differences between the 
immune responses to mycobacteria in the clinically diagnosed 
vs microbiologically confirmed TB groups. It was also somewhat 
FigUre 4 | Bcg-induced iFnγ production by cD4+, cD8+, and γδ+ T cells and regulatory T cells are increased following treatment compared to 
diagnosis and compared to levels in healthy children. Frequencies of IFNγ-producing CD4+ T cells (a,D), γδ+ T cells (B), or CD8+ T cells (c) or IL22-producing 
CD4+ T Cells (e) as detected by an intracellular cytokine assay following stimulation of whole blood with BCG for 20 h (a,B,c,e) or for 6 days (D) are shown. 
CD4+CD25+CD39+FOXP3+ regulatory T cells in unstimulated blood are shown (F). The assays were performed in children with pulmonary TB (PTB) (n = 48), 
extrapulmonary TB (EPTB) (n = 28) at the time of diagnosis and following treatment for tuberculosis (TB), or at recruitment in the case of children with no evidence of 
TB sensitization or disease (healthy) (n = 83). Horizontal bars represent median values. The dotted line represents a cutoff of 0.01 for a positive response. p-Values 
calculated by Mann–Whitney are displayed.
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surprising that the median age of children with EPTB was 5 years, 
since EPTB is historically associated with younger children. 
The median age of 96 children with EPTB recruited as part of 
a parallel diagnostic study in Cape Town was 48.9 months also 
(personal communication). This may reflect protection conferred 
by BCG vaccination at birth or could represent a location bias 
because of recruitment in hospital rather than in the community. 
Additionally, much of the EPTB was either bone, joint, or pleural 
disease, rather than miliary or disseminated disease which is 
normally described in the younger infants.
A limitation of our study is the relatively short duration of 
follow-up of the TB cohort for 6 months. Repeating the assays 
after a period of 2  years to determine whether the increased 
responses observed following 6  months of treatment returned 
to healthy control levels with time could be of interest. Despite 
designing our study to be age-matched with the expectation that 
children under 2 years would present with extrapulmonary TB, 
the children with extrapulmonary TB were older. Although some 
immune responses are known to mature with age, antigen-specific 
immune responses to BCG in infants are comparable to those 
seen in adults (40). A further limitation of the study was the het-
erogeneity of disease in the EPTB cohort, as children with bone or 
joint TB may represent a different immunological pathogenesis 
than disseminated miliary TB or TB meningitis. The median age 
remained the same in the subgroups, but the numbers in each 
group were too small to reach significant conclusions. A further 
limiting factor is that the assays were performed only in blood, 
which may not reflect mechanisms of disease in the lung or other 
sites of disease, but obtaining samples from the site of disease in 
children is challenging.
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In conclusion, we report for the first time that regulatory 
T cells are increased in patients with active TB disease, but that 
they do not distinguish between EPTB and PTB. CD4 effector 
T  cell responses, typically used in diagnostics and as markers 
of vaccine efficacy, do not distinguish between TB disease and 
healthy children in this cohort, but we report suppressed levels of 
pro-inflammatory cytokines and γδ T cells cytokine responses in 
children with TB disease compared to healthy controls. However, 
this does not explain why some children develop EPTB and 
others PTB. Further investigation of the relationship between 
regulatory T  cells and innate immune responses is required to 
define correlates of immune protection associated with clinical 
manifestations of childhood TB.
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